Treatment of COVID-19 Pneumonia and Acute Respiratory Distress With Ramatroban, a Thromboxane A2 and Prostaglandin D2 Receptor Antagonist: A Four-Patient Case Series Report

Treatment of COVID-19 Pneumonia and Acute Respiratory Distress With Ramatroban, a Thromboxane A2 and Prostaglandin D2 Receptor Antagonist: A Four-Patient Case Series Report

Hypoxemia in COVID-19 pneumonia is associated with hospitalization, mechanical ventilation, and mortality. COVID-19 patients exhibit marked increases in fatty acid levels and inflammatory lipid mediators, predominantly arachidonic acid metabolites, notably thromboxane B2 >> prostagland...

Full description

Bibliographic Details
Main Authors: Martin L. Ogletree, Kate Chander Chiang, Rashmi Kulshrestha, Aditya Agarwal, Ashutosh Agarwal, Ajay Gupta
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Pharmacology
Subjects:
SARS-CoV-2
COVID-19
ARDS
hypoxemia
thromboxane A2
ramatroban
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.904020/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.904020/full

Similar Items